Transaction · 0001918845-26-000029

Doyle Mittie

Doyle Mittie, CMO, reported an open-market or private sale at Avalo Therapeutics, Inc. involving 1000.000000 shares for an estimated $20000.00. Reported holdings after the transaction were 51776.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCMO
AVTXAvalo Therapeutics, Inc.
Trade date
Aug 17, 2026
Filing date
Aug 19, 2026
View on SEC Insider profile
Estimated value-$20.0kShares × reported price
Shares traded1.00k$20.00 per share
Holdings after51.7kDirect
% of reported position traded1.89%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 52,776 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

AVTX price since this filing

Daily closing prices, with the filing date and available return windows
AVTX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -6.7%1w ago -4.7%1d ago -5.6%
Returns since7d -1.0%30d -20.1%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001918845-26-000029
Common Stock
Transaction date
Aug 17, 2026
Filed Aug 19, 2026, 08:10 PM · 2d delay
Shares
1,000 sh
$20.00 per share
Estimated value
-$20.0k
Computed from shares × price
Holdings after
51,776 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

  2. F2

    The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's contin…

Original filing · 0001918845-26-000029
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

AVTX